scholarly journals The role of barriers to care on the propensity for hepatitis C virus nonreferral among people living with HIV

AIDS ◽  
2020 ◽  
Vol 34 (11) ◽  
pp. 1681-1683
Author(s):  
Edward R. Cachay ◽  
Francesca J. Torriani ◽  
Lucas Hill ◽  
Sonia Jain ◽  
Azucena Del Real ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Barriers To Care ◽  
People Living With Hiv ◽  
Living With Hiv

scholarly journals Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV

AIDS ◽  
2020 ◽  
Vol 34 (4) ◽  
pp. 599-608 ◽  
Author(s):  
Caroline Besson ◽  
Nicolas Noel ◽  
Remi Lancar ◽  
Sophie Prevot ◽  
Michele Algarte-Genin ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
People Living With Hiv ◽  
B Virus ◽  
Living With Hiv ◽  
Lymphoma Risk

scholarly journals Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV

AIDS ◽  
2020 ◽  
Vol 34 (9) ◽  
pp. 1347-1358
Author(s):  
Samira Hosseini-Hooshyar ◽  
Marianne Martinello ◽  
Jasmine Yee ◽  
Phillip Read ◽  
David Baker ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Universal Access ◽  
People Living With Hiv ◽  
Reinfection Rate ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Living With Hiv

scholarly journals Association between chronic hepatitis C virus infection and myocardial infarction in people living with HIV in the United States

2018 ◽  
Author(s):  
Jessica Williams-Nguyen ◽  
Stephen E Hawes ◽  
Robin M Nance ◽  
Sara Lindström ◽  
Susan R Heckbert ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
The United States ◽  
Hcv Rna ◽  
High Risk Population ◽  
People Living With Hiv ◽  
Extrahepatic Manifestations ◽  
Chronic Hcv ◽  
Living With Hiv

AbstractHepatitis C virus (HCV) is common among people living with HIV (PLWH). The potential for extrahepatic manifestations of HCV, including myocardial infarction (MI), is a topic of active research. MI is classified into types, predominantly atheroembolic Type 1 MI (T1MI) and supply-demand mismatch Type 2 MI (T2MI). We examined the association between HCV and MI in the CFAR Network of Integrated Clinical Systems (CNICS), a multi-center clinical cohort of PLWH. MIs were centrally adjudicated and categorized by type using the Universal MI definition. We estimated the association between chronic HCV (RNA+) and time to MI adjusting for demographic characteristics, cardiovascular risk factors, clinical characteristics and substance use. Among 24,755 PLWH aged ≥18, there were 336 T1MI and 330 T2MI during a median of 4.2 years of follow-up. HCV was associated with a 68% greater risk of T2MI (adjusted hazard ratio (aHR) 1.68, 95% CI: 1.22, 2.30) but not T1MI (aHR 0.96, 95% CI: 0.63, 1.45). In a cause-specific analysis of T2MI, HCV was associated with a 2-fold greater risk of T2MI attributed to sepsis (aHR 2.26, 95% CI: 1.34, 3.81). Extrahepatic manifestations of HCV in this high-risk population are an important area for continued research.

scholarly journals Evaluation of Epidemiologic Peculiarities of HIV-Infection and Genotype Distribution of Hepatitis C Virus among People Living with HIV in Constituent Entities of the Far Eastern Federal District

2021 ◽  
Vol 20 (5) ◽  
pp. 79-88
Author(s):  
E. A. Bazykina ◽  
V. B. Turkutukov ◽  
O. E. Trotsenko ◽  
V. O. Kotova ◽  
L. A. Balakhontseva
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hiv Infection ◽  
Chronic Hepatitis C ◽  
Molecular Genetic ◽  
Hiv Positive ◽  
People Living With Hiv ◽  
Genotype Distribution ◽  
Living With Hiv

Relevance. Monitoring the genotypic diversity of the hepatitis C virus as well as its prevalence in the population, including in certain population groups, is an important public health task.Aim. To analyze main epidemiological indices (incidence and prevalence) among people living with HIV and evaluate abundance of chronic hepatitis C among them, reveal molecular-genetic distribution of hepatitis C virus (HCV) isolated from HIV-positive people living in the Far Eastern Federal district (FEFD) of the Russian Federation.Materials and methods: a retrospective epidemiological analysis including estimation of HIV-infection incidence and prevalence as well as percent of HIV-positive people suffering from chronic viral hepatitis C was conducted for nine constituent entities of the FEFD. Molecular genetic analysis included evaluation of 120 samples of serum positive for HCV RNA that was obtained from people diagnosed with HIV-infection. A type-specific commercial PCR test-kit as well as partial sequencing by Sanger of HCV NS5B gene (241 bp and 350 bp) were utilized in order to specify HCV genotypes.Results and discussion: in total 26.26% of people living with HIV were registered for regular medical examination due to chronic hepatitis C in the FEFD in year 2019. Their percentage has grown over a 5-year period. Dominant HCV subtype among surveyed HIV-positive people was subtype 3a followed by HCV subtype 1b. HCV genotype 2 and subtype 1a were detected less frequently and were identified as minor genotypes. Genotype distribution among people aged under 35 years was more significant in comparison with older citizens. Some regional particularities were discovered. For example, HCV genotype 2 was registered more frequently in the Khabarovsk krai compared to mean estimated value of the sampling collection. Subtype 1b was dominant in Republic Sakha (Yakutia).Conclusion: an increase in percent of HIVinfected people suffering from chronic hepatitis C has been noted during a 5-year period. Should be noted that the value varies in different constituent entities ofthe FEFD. Molecular-genetic analysis showed general prevalence of HCV 3a subtype while 1b HCV subtype is dominant in the Russian Federation in patients suffering from HCV-monoinfection as well as in those infected with HIV and HCV.

scholarly journals Progression to hepatitis C virus micro-elimination in people living with HIV in Spain

2020 ◽  
Author(s):  
Antonio Rivero-Juarez ◽  
Francisco Tellez ◽  
Maria Isabel Mayorga ◽  
Dolores Merino ◽  
Nuria Espinosa ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
People Living With Hiv ◽  
Living With Hiv

scholarly journals Seroprevalence of Hepatitis C Virus in HIV/AIDS Patients in Jos, Nigeria

1970 ◽  
Vol 1 (1) ◽  
pp. 28-33 ◽  
Author(s):  
Lohya Nimzing ◽  
Bisayo Busari ◽  
Nimzing G Ladep
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Diseases ◽  
Hcv Infection ◽  
People Living With Hiv ◽  
Chronic Liver Diseases ◽  
Living With Hiv ◽  
Hiv Aids

Introduction: Hepatitis C Virus (HCV) infection is a life threatening infection and is more serious in people living with HIV/AIDS (PLWHA). It leads to liver damage more quickly and may also affect the treatment of HIV infection. This study was aimed at determining the seroprevalence of HCV, possible risk factors for HCV infection and highlighting the importance of HCV screening in PLWHA in Jos, Nigeria. Materials and Methods: One hundred and eighty two blood samples were collected from confirmed HIVpositive patients attending clinics at the Faith Alive Hospital in Jos for the detection of anti-hepatitis C antibodies. An enzyme linked immunosorbent assay (ELISA), DIALABTM HCV Ab test kit (DIALAB GmbH, Australia) was used for the analysis. Results: Sixty one of the 182 samples tested positive giving a co-infection rate of 33.9%. Old age and low educational levels of the patients were found to be associated with HCV/HIV co-infection (P<0.05). However, the patient's occupation and marital status and the possible risk factors analyzed which included: histories of blood transfusion, sexually transmitted infection (STIs) apart from HIV, surgery, multiple sex partners and injecting drug use were not associated with HCV infection (P>0.05) for the subjects screened. Also, the CD4 cell count ranges of patients and the use of antiretroviral therapy were not associated with HCV infection (P>0.05). Conclusion: The high HCV/HIV co-infection rate observed indicates a possible increase in the development of chronic liver diseases and hepatocellular carcinoma in these patients. Therefore, increasing education on HCV infection and routine screening of HIV patients for anti-HCV antibodies is critical. Key words: Hepatitis C virus, people living with HIV/AIDS (PLWHA), anti-hepatitis C antibodies, chronic liver diseases, hepatocellular carcinoma.      doi: 10.3329/blj.v1i1.2622 Bangladesh Liver Journal Vol.1(1) 2009 p.28-33 

Impact of hepatitis C virus antibody positivity on mortality and causes of death in people living with HIV in Georgia

2019 ◽  
Vol 30 (12) ◽  
pp. 1185-1193
Author(s):  
Nikoloz Chkhartishvili ◽  
Natalia Bolokadze ◽  
Nino Rukhadze ◽  
Natia Dvali ◽  
Akaki Abutidze ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Proportional Hazards ◽  
Multivariable Analysis ◽  
Cox Proportional Hazards ◽  
People Living With Hiv ◽  
Hcv Therapy ◽  
Living With Hiv ◽  
Related Mortality

Hepatitis C co-infection in people living with HIV (PLWH) is common in Georgia. Antiretroviral therapy (ART) is widely available in the country since 2004, and from 2011, patients have unlimited access to hepatitis C virus (HCV) treatment. A retrospective nationwide cohort study included adult PLWH diagnosed between 2004–2016, who were followed up until 31 December 2017. Predictors of mortality were assessed in Cox proportional hazards regression model. A total of 4560 persons contributed 22,322 person-years (PY) of follow-up, including 2058 (45.1%, 10,676 PY) anti-HCV+ patients. After the median 4.1 years of follow-up, 954 persons died, including 615 anti-HCV+ patients. Persons with HCV had higher overall mortality compared to HIV monoinfection (5.76/100 PY vs. 2.91/100 PY, p < 0.0001). In multivariable analysis, anti-HCV positivity was significantly associated with mortality (adjusted hazard ratio: 1.42, 95% CI: 1.09–1.85). Among anti-HCV+ persons, liver-related mortality due to viral hepatitis before the availability of HCV therapy (2004–2011) was 2.11 cases per 100 PY and this decreased to 0.79 cases per 100 PY after 2011 (p < 0.0001). AIDS remained the leading cause of death prior to and after 2011. Wide availability of ART and anti-HCV therapy translated into a significant decline in mortality including due to liver-related causes. Improving earlier diagnosis will decrease excess AIDS-related mortality among people living with HIV/HCV co-infection.

Sign in / Sign up

Export Citation Format

Share Document